TABLE 4.
Summary of results of HPLC assays for artesunate and DHAa
| Variable | Oral administration
|
Convalescent phase
|
Intravenous administration
|
|||
|---|---|---|---|---|---|---|
| Artesunateb | DHAc | Artesunate | DHA | Artesunate | DHA | |
| No. of patients | 3 | 3 | 1 | 1 | 2 | 2 |
| AUC0–24 (ng · h/ml) | 210 (70–667) | 1,334 (1,018–2,673) | 317 | 829 | 1,056 (322–1789) | 3,999 (2,360–5,637) |
| k01 (h−1) | 10.50 (2.55–47.91) | 9.47 (2.36–9.69) | 0.618 | 11.95 | ||
| k10 (h−1) | 1.29 (1.05–1.97) | 1.06 (1.02–1.46) | 0.623 | 0.248 | 3.00 (0.96–5.05) | 1.93 (1.02–2.84) |
| thalf (h) | 0.54 (0.35–0.66) | 0.65 (0.47–0.68) | 1.11 | 2.79 | 0.43 (0.14–0.72) | 0.46 (0.24–0.68) |
| Tlag (h) | 0.19 (0.00–0.25) | 0.22 (0.14–0.45) | 0.27 | 0.25 | ||
| Tmax (h) | 0.50 (0.25–0.50) | 0.75 (0.5–1.0) | 3 | 1 | ||
| Cmax (ng/ml)d | 198 (61–510) | 1,052 (817–2,853) | 98 | 294 | ||
| V (liters/kg) | 7.1 (1.8–31.4) | 1.49 (0.68–1.69) | 8.75 | 7.75 | 3.23 (0.62–5.84) | 0.50 (0.36–0.64) |
| CL (liters/kg/h) | 9.51 (2.99–32.80) | 1.50 (0.75–2.24) | 6.32 | 2.41 | 4.38 (3.19–5.58) | 0.84 (0.66–1.01) |
b
To convert artesunate in nanograms per milliliter to nanomoles per liter, multiply by 2.601.
c
To convert DHA in nanograms per milliliter to nanomoles per liter, multiply by 3.517.
d
Cmax is the observed value for the oral administration data sets and the extrapolated value for the intravenous administration data sets.